GW 468816
- Generic Name
- GW 468816
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
GW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.
- Indication
Investigated for use/treatment in tobacco dependence.
- Associated Conditions
- -
- Associated Therapies
- -
Effectiveness of GW468816, an NMDA Glycine Site Antagonist, for Prevention of Relapse to Smoking
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 264
- Registration Number
- NCT00218465
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸McLean Hospital, Brain Imaging Center, Belmont, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath